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KASPER implementation. Those who do perceive a change are nearly equally di-
vided between an increase and decrease in dispensing. Overall, the majority of
respondents believe that KASPER is an effective tool to reduce drug abuse, diver-
sion, and doctor shopping. Further research is necessary to assess the full effec-
tiveness of PDMPs.
PHP94
THE US ORPHAN DRUG LANDSCAPE: BEFORE AND AFTER EU ORPHAN DRUG
LEGISLATION OF 2000
Bachman EM, Kumar J, Zaidi Q
Heron Evidence Development, LLC., Somerville, NJ, USA
OBJECTIVES: To encourage the development of orphan drug (OD) products, the
European Union (EU) approved OD legislation in 2000, mirroring the US legislation
passed in 1983. For the first time in history, these products were recognized as
different fromother drug products on a global level. Given this newglobal incentive
for OD development, an increased focus on developing these products was ex-
pected. The objective of this research is to quantify a change in the rate of global OD
development asmeasured by the rate of US Food &Drugs Administration (FDA) OD
designations.METHODS: All history within the OD database from the FDA website
was included. The OD status, designation date, and contact company fields were
analyzed to evaluate the OD designation rate and location of developers (US or
non-US categories). RESULTS: Therewas a sharp increase in the number of FDAOD
designations after the year 2000, with the rate of OD designations increasing by
475% compared to the prior period. From 1983 until 2000, 516 products received an
FDA OD designation and the average increase in OD designation was 2.5 per year.
From 2000 through 2011, the number of designations was 1266 and average in-
crease in OD designation was 14.7 per year. After 2000, the proportion of OD des-
ignations from non-US countries increased until 2009 when nearly one-third of
products with a new FDA OD designation were from non-US companies.
CONCLUSIONS: The implementation of EU OD legislationmay have contributed to
a change in the number of FDA OD designations per year and the types of compa-
nies developing ODs for the US.With developingmarkets preparing OD legislation,
these policy changes may further stimulate the growth of the OD industry around
the world.
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OBJECTIVES: Most states have implemented prescription drug monitoring pro-
grams (PDMPs) to reduce prescription controlled substance (CS) abuse and diver-
sion. Relatively little is known, however, about their effectiveness in achieving
these goals. The purpose of this project was to assess the perceived impact of the
Kentucky All Schedule Prescription Electronic Reporting program (KASPER) on CS
abuse, diversion and doctor shopping.METHODS: All law enforcement officials in
Kentucky with an active KASPER account (1119) were surveyed via email. Three
hundred forty (340) responses were received yielding a response rate of 30%. Re-
sponses were coded and descriptive analysis was conducted in STATA v11.
RESULTS: Nearly all (99%) law enforcement officials indicated that they had uti-
lized a KASPER report in the past and, on average, request 3.8 reports permonth for
use in drug diversion investigations. When asked for their opinion on how KASPER
has affected health care provider behavior, the majority (70%) believed that phar-
macists had not altered the stocking and dispensing of CS; however, respondents
were split on their opinion of prescriber behavior. Nearly half (45%) thought pre-
scribers had altered their prescribing of CS.With respect to law enforcement use of
KASPER reports as an investigative tool, 67% of respondents indicated that infor-
mation contained in the report confirmed their decision to proceed with an inves-
tigation while 14% stated that the report caused them to close or dismiss pursuit of
an investigation. Most (93%) respondents believe KASPER is an effective tool for
reducing abuse and diversion while 90% believe it is an effective tool to reduce
doctor shopping. CONCLUSIONS: Law enforcement officials believe that KASPER
reports are a valuable tool when conducting investigations. Overall, the vast ma-
jority of respondents perceive KASPER as an effective tool to reduce drug abuse,
diversion and doctor shopping. Further research is needed to directly assess the
effectiveness of PDMPs.
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OBJECTIVES: A growing global concern is the substantial prevalence of avoidable
chronic disease states, which account for more than 75% of US health care expen-
ditures (CDC, 2010). In response, the utilization of wellness programs by stake-
holder groups to address modifiable risk factors for chronic disease states has
increased. However, the broad variation in perceived value drivers by stakeholders
has influencedwidespreadwellness programadoption. This studywas undertaken
to identify and evaluate critical clinical and economic drivers of wellness technol-
ogy and program adoption. METHODS: A comprehensive review of wellness pro-
gram design, utilization, and adoption drivers was conducted. Subsequently, an in
depth interview program of US stakeholders including payers, clinicians, employ-
ers and wellness program providers was performed. The interviews were designed
to evaluate stakeholder perceptions of value drivers and measurements of well-
ness program benefit. RESULTS:Our data suggest that effective drivers of wellness
program adoption are measurable with defined clinical or economic benefit(s).
Optimizing technology utilization, altering negative patient behaviors and incent-
ing patient adherence are key factors in this regard. However, stakeholder percep-
tions regarding the identification and evaluation ofwellness programsuccessmea-
surements varied substantially. Moreover, stakeholder alignment regarding these
measurements may be a key driver of program adoption. CONCLUSIONS: This
study suggests that the demonstrated clinical and economic impact of wellness
programs influence perceptions of value. Despite wellness programs trending to-
wards addressing cardiovascular disease, diabetes and metabolic syndrome/obe-
sity, harmonization of program evaluation criteria has not emerged. Program
adoption is can be affected by the lack of aligned perceptions of value within
stakeholder groups. Properly alignedmetrics of clinical and economic benefit along
with optimization of technology utilization, patient adherence and return on in-
vestment are critical drivers of wellness program adoption. Guidance is needed on
efficientmeasures of clinical and economic outcomes to improve design and adop-
tion of wellness programs.
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OBJECTIVES: This study sought to understand the current use of payer-industry
partnerships in key influence markets and to gain insight into regional perspec-
tives on the current and future use of payer-industry partnerships. METHODS:
Primary researchwas conducted through 57, 30-60minute interviews of key stake-
holders from industry and regulatory agencies across 9majormarkets (EU 5, United
States, Japan, Canada, and Australia). Interview questionnaires were designed to
understand perceptions regarding current partnerships as well as awareness of
emerging models. Primary data was complemented by reviews of published and
gray literature, government and other relevant agency websites, and IHS proprie-
tary Healthcare and Pharmaceutical content. RESULTS: Two broad categories of
partnerships were predominantly used across the countries examined – partner-
ships for reimbursement decision-making (e.g. risk-sharing agreements) and part-
nerships downstreamof reimbursement (e.g. diseasemanagement programs). One
key findingwas the acceptance of payer-industry partnerships as a necessary prac-
tice as opposed to short term trend. According to interviewees, partnerships are
increasingly becoming a necessity because of gaps in funding. Given such chal-
lenges, stakeholders are more willing to consider novel opportunities for collabo-
ration with industry. Secondly, this study found a lack of agreement on the pre-
ferred type of payer-industry partnerships. For example, the United States has
used diseasemanagement systems and other downstreampartnerships as amain-
stay. Payer sentiment, however, is that these practices are flawed, with many US
stakeholders looking to risk sharing for future partnerships. Conversely, many
stakeholders in the UK have expressed interest in moving away from risk sharing
to adopt more downstream partnerships. CONCLUSIONS: Payer-industry partner-
ships are making the transition from being experimental options to permanent
practice within health care systems. Countries are looking at methods used in
other regions to explore new opportunities to expand partnerships. There is a lack
of international alignment, however, onwhich partnershipswill bemost beneficial
in the future.
PHP98
THE FUTURE OF ALTERNATIVE PRICING/RISK-SHARING AGREEMENTS IN THE
UNITED STATES
Goldenberg D, Bachman EM
Heron Evidence Development, LLC., Somerville, NJ, USA
OBJECTIVES: Due to the rising cost of health care in the United States, payers have
begun to place an increased emphasis on cost when evaluating new submissions
for formulary access. Our objective was to evaluate the US payer perception of
alternative pricing/risk-sharing (AP/RS) agreements focusing on: 1) assessing the
success of previously implemented AP/RS agreements in the United States, and 2)
evaluating conceptual AP/RS structures with payers to assess preference of
concepts.METHODS: An online survey was conducted to evaluate the perceptions
of a broad spectrum of US payers on AP/RS agreements (n19). Following the sur-
vey, in-depth interviews (n5) were conducted with US national and regional pay-
ers to gain additional insight. RESULTS: More than 90% of US payers were inter-
ested in AP/RS agreements. Payers believed that these types of agreements could
be implemented for both their pharmacy (84% of payers) and medical (42% of
payers) benefits. Over half the payers (52%) believed that AP/RS agreements should
be considered for orphan diseases, 68% believed that they should be considered for
other rare diseases, and 73% believed that they should be considered for chronic
high-prevalence diseases. Payers expressed concerns that previous AP/RS agree-
ments were not successful due to a lack of independent data reporting and an
imbalance in risk-sharing. Payers (73%) showed a preference for “pay-for-perfor-
mance” schemes that offered predictable cost outlays and mutually beneficial risk
agreements with clearly-defined and independently-verified success markers.
CONCLUSIONS: US payers are keenly aware of alternative pricing/risk-sharing
agreements and foresee themplaying a larger role in future US negotiations if clear
cost and risk benchmarks are established.
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